Denny's rallies after Wedbush turns bullish on Keke's upside, earnings potential
Denny's (DENN) sees a rally after Wedbush upgrades stock on growth potential and expected earnings beat in Q4.
Hosted on MSN14h
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation
Fintel reports that on February 6, 2025, Wedbush initiated coverage of Bicara Therapeutics (NasdaqGM:BCAX) with a Outperform ...
Denny’s upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Nick Setyan upgraded Denny’s (DENN) to Outperform from Neutral with a price target of $10, up from $6. First, the firm believes ...